Page 534 - பல்கலைக்கழகம் ஆஃப் வடக்கு கரோலினா இல் தேவாலயம் மலை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Has The World Ended Yet? Students Reflect On Letters To The Future
wunc.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wunc.org Daily Mail and Mail on Sunday newspapers.
Covid: Schools & Workplace | My Clinton News
myclintonnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from myclintonnews.com Daily Mail and Mail on Sunday newspapers.
As part of MedPage Today s review of the past year s top stories, here we summarize developments on the abnormal COVID-related clotting first reported by Chinese clinicians, as we reported on March 24, 2020 (republished here).
Clotting problems with severe COVID-19 became clear in the early days of the pandemic; now at around the 1-year mark of the first cases, research is just beginning to reveal what prophylactic strategies are best.
By March, Chinese clinicians treating the initial onslaught of cases there pointed to endothelial damage and clotting in not only the lungs but also the heart and other organs. They argued for prophylactic anticoagulation of all these patients with severe disease regardless of meeting typical hospital criteria for it.
Hadley Green / Courtesy of Emma Peaslee
Emma Peaslee is a 2020-21 Kroc Fellow. Before coming to NPR, she reported for Atlanta s member station, WABE. She covered public forums about toxic chemicals leaking into neighborhoods, the world s largest 10K race, and the federal government s plan to resume executions. Peaslee has a master s degree in journalism from the University of North Carolina at Chapel Hill where her work received the 2020 Edward R. Murrow Award for best student newscast. She is a Minnesota native.
DURHAM –IMMvention Therapeutix, which nearly won a pitch competition from LaunchBio this summer, has won a bigger deal with investors.
Four backers are putting just over $3.9 million into the startup that is focusing on therapies to combat inflammation, according to an SEC filing.
The mix of equity and options fell just short of the $4.4 million the company sought.
IMMvention
The 4-year-old Durham company was one of three finalists in LaunchBio’s Big Pitch competition for the most promising life science or biotech startup in the United States.
IMMvention had won the competition among Durham-area startups earlier in the summer, beating out the likes of CasTag Biosciences, PhosphoGam, Praetego, and TreeCo to advance to the national round.
vimarsana © 2020. All Rights Reserved.